Evidence map›Paper›PMID 34952905›Full record

ArticleScientific reports2021

CD105

Måns Kadefors, Sara Rolandsson Enes, Emma Åhrman, Barbora Michaliková, Anna Löfdahl, Göran Dellgren, Stefan Scheding, Gunilla Westergren-Thorsson

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. CD105Breast cancer research : BCR · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Role and mechanism of CD90Molecular medicine (Cambridge, Mass.) · 2023
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Måns KadeforsDepartment of Experimental Medical Science, Lund University, Lund, Sweden. mans.kadefors@med.lu.se.
Sara Rolandsson EnesDepartment of Experimental Medical Science, Lund University, Lund, Sweden.
Emma ÅhrmanDivision of Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Barbora MichalikováDepartment of Experimental Medical Science, Lund University, Lund, Sweden.
Anna LöfdahlDepartment of Experimental Medical Science, Lund University, Lund, Sweden.
Göran DellgrenDepartment of Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Göteborg, Sweden.
Stefan SchedingDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Gunilla Westergren-ThorssonDepartment of Experimental Medical Science, Lund University, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal cells are important components of specified niches in the lung, and can mediate a wide range of processes including tissue regeneration and repair. Dysregulation of these processes can lead to improper remodeling of tissue as observed in several lung diseases. The mesenchymal cells responsible remain poorly described, partially due to the heterogenic nature of the mesenchymal compartment and the absence of appropriate markers. Here, we describe that CD105

Indexed as

BiomarkersCells, CulturedFibroblastsHumansLungPrimary Cell CultureBiomarkers

Identifiers

PMID34952905
PMCPMC8709856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.